Exact Sciences shares surged nearly 18% in pre-market trading to $101.67 following Abbott's announcement of a $23 billion acquisition deal. Abbott has agreed to purchase Exact Sciences at $105 per share, a 21.8% premium over the previous closing price of $69.68. The acquisition, expected to close in the second quarter of 2026, will enhance Abbott's position in the $60 billion U.S. cancer diagnostics market. Exact Sciences' product portfolio, including Cologuard and Oncotype DX, is a key driver, with Oncotype DX projected to generate over $3 billion in revenue in 2025.